

4

RECEIVED
CENTRAL FAX CENTER

MAY 04 2006

OFFICIAL COMMUNICATION FACSIMILE

TO THE ATTENTION OF:

MAIL STOP AMENDMENT

CENTRAL FAX NO: 571-273-8300

Number of pages including this page 4 pages

Applicant :	Beverly L. Davidson et al.	Art Unit :	1635
Serial No. :	10/522,954	Examiner :	Unknown
Filed :	January 31, 2005	Docket :	17023.045US2
Title :	ALLELE-SPECIFIC SIRNA-MEDIATED GENE SILENCING		


MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attached to this facsimile communication cover sheet is a Transmittal Form, Information Disclosure Statement (1 pg.), Form 1449 (1 pg.) and copy of one (1) cited reference, faxed this 4th day of May, 2006, to the Central Fax Center, U.S. Patent and Trademark Office.

Respectfully submitted,

Date: May 4, 2006


Peter J. Malen
Reg. No. 44,894

Customer Number 53137

Viksnins Harris & Padys PLLP
PO Box 111098
St. Paul, MN 55111-1098
Telephone: (952) 876-4094
Facsimile: (952) 876-4098

NOTE: This facsimile is intended for the addressee only and may contain privileged or confidential information. If you have received this facsimile in error, please immediately call us collect at (952) 876-4091 to arrange for its return. Thank you.

BEST AVAILABLE COPY

MAY 04 2006

S/N 10/522,954PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Beverly L. Davidson et al.	Examiner:	Unknown
Serial No.:	10/522,954	Group Art Unit:	1635
Filed:	January 31, 2005	Docket:	17023.045US2
Title:	ALLELE-SPECIFIC SIRNA-MEDIATED GENE SILENCING		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. § 1.97, no fee or statement is required with the Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 503503 in order to have this Information Disclosure Statement considered. The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,
Beverly L. Davidson et al.
By their Representatives,
Viksnins Harris & Padys PLLP
P.O. Box 111098
St. Paul, MN 55111
952 876-4094

Date May 04, 2006By 
Peter L. Malen
Reg. No. 44,894

CERTIFICATE UNDER 37 CFR 1.8: I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 4 day of May, 2006.

Lynda Mau
Name
Signature

BEST AVAILABLE COPY

<small>Substitute for form 1449A/PTO and/or 1449B/PTO</small> INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use as many sheets as necessary)</small>	<small>Complete if Known</small>	
	Application Number	10/522,954
	Filing Date	January 31, 2005
	First Named Inventor	Davidson
	Group Art Unit	1635
	Examiner Name	Unknown
Sheet 1 of 1		Attorney Docket No: 17023.045US2

US PATENT DOCUMENTS			
Examiner Initials *	US Document Number	Publication Date	Name of Patentee/Applicant of Document

FOREIGN PATENT DOCUMENTS			
Examiner Initials *	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Include last name of the first author, "Title of the Article", <u>Title of the Source</u> (book, magazine, journal, serial, symposium, catalog, etc.), <u>Volume-Number</u> , page(s) and (date).
	Goto et al., "Suppression of Huntingtin Gene Expression by siRNA: A Possible Therapeutic Tool for Huntington's Disease", Neurology, 60(5), Suppl 1, page A286, Abstract PD4.055 (2003).

EXAMINER

DATE CONSIDERED

Substitute Information Disclosure Statement Form (PTO-1449)
* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP 809. Date line through citation if not considered. Include copy of this form with next communication to Applicant.

AVAILABLE ON